Illinois General Assembly - Full Text of SB1934
Illinois General Assembly

Previous General Assemblies

Full Text of SB1934  98th General Assembly

SB1934 98TH GENERAL ASSEMBLY

  
  

 


 
98TH GENERAL ASSEMBLY
State of Illinois
2013 and 2014
SB1934

 

Introduced 2/15/2013, by Sen. Antonio Muñoz - Iris Y. Martinez - Pamela J. Althoff - Melinda Bush

 

SYNOPSIS AS INTRODUCED:
 
225 ILCS 85/19.5 new

    Amends the Pharmacy Practice Act. Provides that a pharmacist may substitute a prescription biosimilar product for a prescribed biological product under certain circumstances. Provides that the Board shall adopt rules for compliance with these provisions. Effective immediately.


LRB098 10574 MGM 40827 b

FISCAL NOTE ACT MAY APPLY

 

 

A BILL FOR

 

SB1934LRB098 10574 MGM 40827 b

1    AN ACT concerning regulation.
 
2    Be it enacted by the People of the State of Illinois,
3represented in the General Assembly:
 
4    Section 5. The Pharmacy Practice Act is amended by adding
5Section 19.5 as follows:
 
6    (225 ILCS 85/19.5 new)
7    Sec. 19.5. Biosimilars products.
8    (a) For the purposes of this Section:
9    "Biological product", "biosimilar", and "interchangeable"
10have the same meanings as under Section 351 of the Public
11Health Service Act (42 U.S.C. 262).
12    "Prescription", with respect to a biological product,
13means a product that is subject to Section 503 (b) of the
14Federal, Food, Drug, and Cosmetic Act (21 U.S.C. 353(b)).
15    (b) A pharmacist may substitute a prescription biosimilar
16product for a prescribed biological product only if:
17        (1) the biosimilar product has been determined by the
18    United States Food and Drug Administration to be
19    interchangeable with the prescribed biological product;
20        (2) the prescribing physician does not designate
21    orally, in writing, or electronically that substitution is
22    prohibited in a manner inconsistent with Section 25 of this
23    Act;

 

 

SB1934- 2 -LRB098 10574 MGM 40827 b

1        (3) the pharmacy informs the patient of the
2    substitution;
3        (4) the pharmacist informs the prescriber within 5
4    business days of the substitution, including the name and
5    manufacturer of the interchangeable biosimilar dispensed;
6        (5) the pharmacy retains a written record of the
7    interchangeable biosimilar substitution for a period of no
8    less than 5 years.
9    (c) The Board shall adopt rules for compliance with this
10Section.
 
11
12    Section 99. Effective date. This Act takes effect upon
13becoming law.